Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2013

01.01.2013 | Original Paper

Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study

verfasst von: Rensheng Wang, Fang Wu, Heming Lu, Bo Wei, Guosheng Feng, Guisheng Li, Meilian Liu, Haolin Yan, Jinxian Zhu, Yong Zhang, Kai Hu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate long-term outcome in nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy.

Methods

Between January 2006 and August 2008, 300 patients with histologically proven NPC were enrolled in this multicenter prospective study. All patients received definitive IMRT. Cisplatin-based concurrent chemotherapy was given to patients with stages III-IVb disease.

Results

Median follow-up time was 47.1 months (range 11–68 months). Median survival time was not reached. For all patients, the 4-year local control (LC), regional control (RC), distant metastasis-free survival (DMFS), and overall survival (OS) were 94.0, 95.1, 85.0, and 86.1 %, respectively. Thirty-five patients experienced locoregional failures: 18 were local only, 15 were regional only, and 2 were both local and regional. Forty-two patients developed distant metastasis. Of these, 32 patients had single organ metastasis, and 10 patients had multiple organ metastasis. The most common acute toxicities were mucositis, dermatitis, and xerostomia. Grade 0–2 mucositis, dermatitis, and xerostomia occurred in 200 patients (66.7 %), 288 patients (96.0 %), and 286 patients (95.3 %), respectively. Grade 3 mucositis, dermatitis, and xerostomia were seen in 100 patients (33.3 %), 12 patients (4.0 %), and 14 patients (4.7 %), respectively. No Grade 4 acute toxicities were observed. The most common late toxicity for 284 patients who survived for more than 2 years was xerostomia. At 3 months after treatment, 16.2 % of patients had Grade 1, 73.6 % had Grade 2, and 10.2 % had Grade 3 xerostomia. However, the severity of xerostomia decreased over time. At 24 months, only 12.3 % of patients had Grade 2 xerostomia, and none had Grade 3 or 4 xerostomia.

Conclusions

IMRT for NPC patients achieved excellent long-term locoregional control (LRC) and OS, with acceptable acute and late toxicities. After the treatment, xerostomia was improved over time. Distant metastasis remained the main cause of failure. More effective systemic therapy is demanding for reducing the risk of distant metastasis.
Literatur
Zurück zum Zitat Cheng JC, Chao KS, Low D (2001) Comparison of intensity-modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 96:126–131PubMedCrossRef Cheng JC, Chao KS, Low D (2001) Comparison of intensity-modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 96:126–131PubMedCrossRef
Zurück zum Zitat Han L, Lin S, Pan J et al (2010) Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer 29:145–150PubMedCrossRef Han L, Lin S, Pan J et al (2010) Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer 29:145–150PubMedCrossRef
Zurück zum Zitat Kam MK, Chau RM, Suen J et al (2003) Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys 56:145–157PubMedCrossRef Kam MK, Chau RM, Suen J et al (2003) Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys 56:145–157PubMedCrossRef
Zurück zum Zitat Kam MK, Leung SF, Zee B et al (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early stage nasopharyngeal carcinoma. J Clin Oncol 25:4873–4879PubMedCrossRef Kam MK, Leung SF, Zee B et al (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early stage nasopharyngeal carcinoma. J Clin Oncol 25:4873–4879PubMedCrossRef
Zurück zum Zitat Kwong DL, Pow EH, Sham JS et al (2004) Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 101:1584–1593PubMedCrossRef Kwong DL, Pow EH, Sham JS et al (2004) Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 101:1584–1593PubMedCrossRef
Zurück zum Zitat Kwong DL, Sham JS, Leung LH et al (2006) Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 64:374–381PubMedCrossRef Kwong DL, Sham JS, Leung LH et al (2006) Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 64:374–381PubMedCrossRef
Zurück zum Zitat Lai SZ, Li WF, Chen L et al (2011) How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80:661–668PubMedCrossRef Lai SZ, Li WF, Chen L et al (2011) How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80:661–668PubMedCrossRef
Zurück zum Zitat Lee N, Xia P, Quivey JM et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12–22PubMedCrossRef Lee N, Xia P, Quivey JM et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12–22PubMedCrossRef
Zurück zum Zitat Lee SW, Back GM, Yi BY et al (2006) Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 65:152–160PubMedCrossRef Lee SW, Back GM, Yi BY et al (2006) Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 65:152–160PubMedCrossRef
Zurück zum Zitat Lee N, Harris J, Garden AS et al (2009) Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 27:3684–3690PubMedCrossRef Lee N, Harris J, Garden AS et al (2009) Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 27:3684–3690PubMedCrossRef
Zurück zum Zitat Lin S, Pan J, Han L et al (2009) Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys 75:1071–1078PubMedCrossRef Lin S, Pan J, Han L et al (2009) Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys 75:1071–1078PubMedCrossRef
Zurück zum Zitat Lu H, Peng L, Yuan X et al (2009) Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia. Cancer Treat Rev 35:345–353PubMedCrossRef Lu H, Peng L, Yuan X et al (2009) Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia. Cancer Treat Rev 35:345–353PubMedCrossRef
Zurück zum Zitat Ng WT, Lee MCH, Hung WM et al (2011) Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 79:420–428PubMedCrossRef Ng WT, Lee MCH, Hung WM et al (2011) Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 79:420–428PubMedCrossRef
Zurück zum Zitat Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981–991PubMedCrossRef Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981–991PubMedCrossRef
Zurück zum Zitat Teo PM, Ma BB, Chan AT (2004) Radiation therapy for nasopharyngeal carcinoma-transition from two-dimensional to three-dimensional method. Radiother Oncol 73:163–172PubMedCrossRef Teo PM, Ma BB, Chan AT (2004) Radiation therapy for nasopharyngeal carcinoma-transition from two-dimensional to three-dimensional method. Radiother Oncol 73:163–172PubMedCrossRef
Zurück zum Zitat Toledano I, Graff P, Serre A et al (2012) Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004–03. Radiother Oncol 103:57–62PubMedCrossRef Toledano I, Graff P, Serre A et al (2012) Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004–03. Radiother Oncol 103:57–62PubMedCrossRef
Zurück zum Zitat Wang J, Shi M, Hsia Y et al (2012) Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation in Northwest China: a pilot study. Radiat Oncol 7:2PubMedCrossRef Wang J, Shi M, Hsia Y et al (2012) Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation in Northwest China: a pilot study. Radiat Oncol 7:2PubMedCrossRef
Zurück zum Zitat Wu S, Xie CY, Jin X et al (2006) Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal carcinoma; a local center’s experience. Int J Radiat Oncol Biol Phys 66:S40–S46CrossRef Wu S, Xie CY, Jin X et al (2006) Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal carcinoma; a local center’s experience. Int J Radiat Oncol Biol Phys 66:S40–S46CrossRef
Zurück zum Zitat Xia P, Fu KK, Wong GW et al (2000) Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48:329–337PubMedCrossRef Xia P, Fu KK, Wong GW et al (2000) Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48:329–337PubMedCrossRef
Zurück zum Zitat Zhao C, Lu L, Han F et al (2005) Preliminary results of intensity-modulated radiation therapy alone for 122 patients with untreated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63:S382CrossRef Zhao C, Lu L, Han F et al (2005) Preliminary results of intensity-modulated radiation therapy alone for 122 patients with untreated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63:S382CrossRef
Metadaten
Titel
Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study
verfasst von
Rensheng Wang
Fang Wu
Heming Lu
Bo Wei
Guosheng Feng
Guisheng Li
Meilian Liu
Haolin Yan
Jinxian Zhu
Yong Zhang
Kai Hu
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-012-1313-0

Weitere Artikel der Ausgabe 1/2013

Journal of Cancer Research and Clinical Oncology 1/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.